Introduction
============

Globally, stroke is the second most frequent cause of mortality and the primary cause of serious long-term disability worldwide ([@b1-mmr-18-02-1513]). Of all strokes, 87% are ischemic ([@b2-mmr-18-02-1513]). Various mechanisms underlying ischemic stroke are driven by cell-cell interactions within brain, including excitotoxicity, calcium dysregulation, oxidative and nitrosative Stress, cortical spreading depolarizations, inflammation, necrosis, necroptosis and autophagy ([@b3-mmr-18-02-1513]). In addition to a narrow therapeutic time window ([@b4-mmr-18-02-1513]), ischemic stroke remains difficult to manage.

Although reperfusion has been proven to be beneficial for ischemic stroke ([@b5-mmr-18-02-1513]), reperfusion may result in detrimental secondary damage, which is termed ischemia/reperfusion (I/R) injury. Early reperfusion of ischemic brain tissue has been associated with various negative consequences, including blood-brain barrier breakdown, which may result in cerebral edema and/or brain hemorrhage, neurovascular damage and neuronal death ([@b6-mmr-18-02-1513]). Angiogenesis and vasculogenesis have also been detected following reperfusion ([@b7-mmr-18-02-1513]). In addition, inflammation is induced by reperfusion injury and contributes negatively to long-term disease prognosis ([@b8-mmr-18-02-1513]). The inflammatory response may result in subsequent oxidative injury, excitotoxicity and neuronal cell death ([@b9-mmr-18-02-1513]). Chemokines, produced by resident microglial cells and other immune cells in the brain, contribute to the recruitment of circulating leukocytes and exaggerate the inflammatory response. Chemokines have been demonstrated to have both deleterious and beneficial roles in ischemia/reperfusion injury ([@b10-mmr-18-02-1513]).

Microarray analysis has been previously employed to identify molecular variations in cerebral I/R injury ([@b11-mmr-18-02-1513],[@b12-mmr-18-02-1513]). However, gene expression profiles at different reperfusion periods have not been investigated extensively. Therefore, the present study employed a microarray dataset from the Gene Expression Omnibus (GEO) database and screened for differentially expressed genes (DEGs) between control samples and cerebral I/R samples at 2, 8 and 24 h post-reperfusion, and subsequently analyzed the functions and interactions of these DEGs. The results of the current study may aid in improving the understanding of the molecular mechanisms underlying cerebral I/R injury.

Materials and methods
=====================

### Microarray data

Microarray gene expression profiles from GSE23160 ([@b12-mmr-18-02-1513]) were obtained from the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>), which is based on the platform of GPL6885 using Illumina MousRef-8 v2.0 Expression BeadChip (Illumina, Inc., San Diego, CA, USA). All of the samples were taken from male C57BL/6J mice (8--10 weeks). Following 2 h suture-induced middle cerebral artery occlusion (MCAO), the animals underwent reperfusion for 2, 8 or 24 h. Tissue extractions at 2, 8 and 24 h post-reperfusion and sham controls (n=4 per group) were included in this dataset.

### Identification of DEGs

GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>), an R-based web application ([@b13-mmr-18-02-1513]), was employed to analyze DEGs between MCAO samples and sham samples. P\<0.05 and \|logFC\|≥1.2 were set as the threshold criteria to identify genes that were differentially expressed in MCAO models. Subsequently, the DEGs at 2, 8 and 24 h post-reperfusion were screened for subsequent analyses. A Venn diagram was produced to indicate the intersection among DEGs in the various MCAO groups using FunRich software (version 2.1.1; [www.funrich.org](www.funrich.org)) ([@b14-mmr-18-02-1513]).

### Functional enrichment analysis of DEGs

To identify the biological processes, cellular components, molecular functions and biological pathways that the DEGs were significantly enriched in, Gene Ontology (GO) enrichment ([@b15-mmr-18-02-1513]) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses ([@b16-mmr-18-02-1513]) were performed using the online tool Database for Annotation, Visualization and Integrated Discovery (DAVID; <http://david.abcc.ncifcrf.gov/>). P\<0.05 was considered to indicate a significantly enriched term or pathway, which was calculated using a hypergeometric test. Heat map illustration of DEGs was performed with heat map illustrator software (version 1.0.3.7; <http://hemi.biocuckoo.org>) ([@b17-mmr-18-02-1513]).

### Construction of the PPI network

To further investigate the underlying molecular mechanisms of cerebral I/R injury, protein-protein interaction (PPI) networks for the DEGs were constructed using the Search Tool for the Retrieval of Interacting Genes (STRING) database (<http://www.string-db.org/>) ([@b18-mmr-18-02-1513]). A combined score of \>0.4 was selected to construct the PPI networks. The obtained PPI networks at 24 h post-reperfusion were subsequently visualized using Cytoscape software (version 3.5.1) ([@b19-mmr-18-02-1513]). Finally, the topological properties of the networks at 2, 8 and 24 h post-reperfusion were analyzed and the degree of each node was calculated; genes with a degree \>10 were defined as hub genes.

Results
=======

### Identification of DEGs

As demonstrated in [Fig. 1](#f1-mmr-18-02-1513){ref-type="fig"}, 32 DEGs at 2 h post-reperfusion, 39 DEGs at 8 h post-reperfusion and 91 DEGs at 24 h post-reperfusion were identified in the MCAO samples compared with the controls. Among them, 15 DEGs were common to all three injury samples, including C-C motif chemokine ligand (CCL)7, suppressor of cytokine signaling 3, CCL4, activating transcription factor 3, lipocalin 2, hemoglobin α adult chain 1, gap junction protein β2, CD14 antigen, CCL3, heat shock protein 1A, S100 calcium-binding protein A8 (calgranulin A), C-X-C motif chemokine ligand 1 (CXCL1), epithelial membrane protein 1, tissue inhibitor of metalloproteinase 1 and zinc finger protein 36, all of which were upregulated in the MCAO samples ([Table I](#tI-mmr-18-02-1513){ref-type="table"}). Heat map and PPI network analysis at 2 and 8 h post-reperfusion are not presented due to the small number of identified DEGs.

### Bioinformatics analyses of DEGs

To further the understanding of the screened DEGs and determine their potential roles following I/R injury, GO functional and KEGG pathway enrichment analyses were performed.

A total of 51 GO enriched terms for biological processes at 2, 8 and 24 h post-reperfusion were obtained. The 10 most enriched GO terms according to the P-value for 2, 8 and 24 h post-reperfusion groups are presented in [Table II](#tII-mmr-18-02-1513){ref-type="table"}. Furthermore, 'chemotaxis' (GO:0006935), 'inflammatory response' (GO:0006954), 'immune response' (GO:0006955), 'G-protein coupled receptor signaling pathway' (GO:0007186), 'response to toxic substance' (GO:0009636), 'neutrophil chemotaxis' (GO:0030593), 'positive regulation of tumor necrosis factor production' (GO:0032760), 'positive regulation of GTPase activity' (GO:0043547), 'lymphocyte chemotaxis' (GO:0048247), 'positive regulation of inflammatory response' (GO:0050729), 'cell chemotaxis' (GO:0060326), 'chemokine-mediated signaling pathway' (GO:0070098), 'positive regulation of ERK1 and ERK2 cascade' (GO:0070374), 'cellular response to interferon-gamma' (GO:0071346), 'cellular response to interleukin-1' (GO:0071347), 'monocyte chemotaxis' (GO:0002548) and 'cellular response to tumor necrosis factor' (GO:0071356) were significantly enriched at all three post-reperfusion time-points (2, 8 and 24 h).

Additionally, DEGs were enriched in various GO cellular component terms; at 2 and 8 h post-reperfusion, DEGs were enriched in 'extracellular region' (GO:0005576), while 'membrane' (GO:0016020) was significantly enriched at both 8 and 24 h post-reperfusion ([Table III](#tIII-mmr-18-02-1513){ref-type="table"}). Furthermore, [Table IV](#tIV-mmr-18-02-1513){ref-type="table"} indicates that DEGs were significantly enriched in 'cytokine activity' (GO:0005125) and 'chemokine activity' (GO:0008009) GO molecular function terms at 2, 8 and 24 h post-reperfusion.

[Table V](#tV-mmr-18-02-1513){ref-type="table"} presents the KEGG pathways that were significantly enriched in DEGs. KEGG analysis indicated that 'chemokine signaling pathway', 'cytokine-cytokine receptor interaction' and 'toll-like receptor signaling pathway' were significantly enriched in DEGs at 2, 8 and 24 h post-reperfusion. Furthermore, as demonstrated in [Fig. 2](#f2-mmr-18-02-1513){ref-type="fig"}, a total of 11 chemokine signaling pathway-associated genes were overexpressed in 24 h post-reperfusion injury samples compared with the sham control samples.

### PPI network analysis

Genes with an interaction degree \>10 in the PPI network analysis of DEGs at 2, 8 and 24 h post-reperfusion were defined as hub genes, which are listed in [Table VI](#tVI-mmr-18-02-1513){ref-type="table"}. CXCL1 was the only gene that was considered to be a hub gene at 2, 8 and 24 h post-reperfusion ([Table VI](#tVI-mmr-18-02-1513){ref-type="table"}). The constructed PPI network of 24 h post-reperfusion samples is presented in [Fig. 3](#f3-mmr-18-02-1513){ref-type="fig"}, which contains 67 nodes and 281 edges. Each node represents a DEG and each edge represents a PPI between two DEGs. At 24 h post-reperfusion, 23 genes served as hub genes, and of these hub genes, CCL2 exhibited the highest degree ([Fig. 3](#f3-mmr-18-02-1513){ref-type="fig"}).

Discussion
==========

In the present study, 32 DEGs at 2 h, 39 DEGs at 8 h and 91 DEGs at 24 h post-reperfusion injury were identified between cerebral I/R and sham control samples. Previous studies have performed bioinformatics analysis to identify DEGs between MCAO models and controls ([@b11-mmr-18-02-1513],[@b20-mmr-18-02-1513]--[@b23-mmr-18-02-1513]). However, to the best of our knowledge, the present study is the first to perform global gene expression profiling at three time-points following reperfusion, and the findings may lead to improvements in the understanding of the pathophysiological process of cerebral I/R injury. DEGs associated with inflammation have previously been associated with cerebral I/R injury ([@b20-mmr-18-02-1513],[@b22-mmr-18-02-1513]), and the results of the present study were consistent with these previous reports, indicating a persistent inflammatory response in cerebral I/R injury.

In the current study, enrichment analysis revealed that 'chemotaxis', 'chemokine activity' and 'chemokine signaling pathway' terms were significantly enriched for the obtained DEGs. Furthermore, members of the chemokine family were the most abundant among the upregulated genes that were common among 2, 8 and 24 h post-reperfusion time-points, including CCL3, CCL4, CCL7 and CXCL1. Chemokines have been reported to have complex and essential roles in I/R injury, which involves extensive leukocyte and neutrophil infiltration, subsequently exaggerating the ischemic area ([@b24-mmr-18-02-1513]). Following ischemic stroke, chemokines are primarily produced by resident microglial cells in the brain and infiltrating immune cells, which leads to further leukocyte recruitment and activation ([@b25-mmr-18-02-1513]). In the present study, CCL2 exhibited the highest degree in the PPI network at 24 h post-reperfusion, which is consistent with previous studies ([@b26-mmr-18-02-1513],[@b27-mmr-18-02-1513]). Accordingly, CCL2 mRNA expression was initially increased at 6 h post-reperfusion, peaking 2 days later. Additionally, CCL3 was previously described to be upregulated post-I/R injury via the induction of monocyte accumulation in the ischemic brain ([@b28-mmr-18-02-1513],[@b29-mmr-18-02-1513]), and the expression of CCL3 post-reperfusion has been reported to be time-dependent ([@b30-mmr-18-02-1513]). CCL7, as a mast cell-derived product, has been reported to be involved in the recruitment of inflammatory cells into the ischemic sites ([@b31-mmr-18-02-1513]), subsequently contributing to stroke pathology ([@b32-mmr-18-02-1513]). CXCL1, identified as a hub gene in the PPI networks at 2, 8 and 24 h post-reperfusion in the present study, was reported to be increased in the cerebrospinal fluid of patients that have suffered from a stroke ([@b33-mmr-18-02-1513]). However, both neurotoxic and neuroprotective effects have been demonstrated for chemokines in post-stroke inflammation ([@b28-mmr-18-02-1513]).

It is established that inflammation is a major contributor to stroke pathophysiology, and the immune system has been implicated in all stages of the ischemic cascade, from the acute damaging events to the progression of tissue repair ([@b34-mmr-18-02-1513]). Microglia cells, which are closely associated with inflammation, were reported to become rapidly activated following ischemia ([@b35-mmr-18-02-1513]). Furthermore, various pro-inflammatory factors, including interleukin (IL)-1β, IL-6, tumor necrosis factor-α, reactive oxygen species, nitric oxide and prostaglandin E2, were reported to be produced by activated microglia and contribute to neuronal death in cerebral ischemia ([@b36-mmr-18-02-1513]). In the present study, specific cytokines were not measured. Further studies are required to investigate the association between the chemokine family and pro-inflammatory cytokines, which further elucidate the pathophysiological process following cerebral I/R injury.

The results of the present study revealed that the toll-like receptor signaling pathway was significantly enriched at 2 h post-reperfusion, suggesting early transcriptional activation. TLR2, a vital factor in the inflammatory response and tissue damage, has been reported to be implicated in cerebral ischemic damage ([@b37-mmr-18-02-1513]). Microglia cells produce cytokines and chemokines following the stimulation of TLR2 ([@b38-mmr-18-02-1513]). Furthermore, leukocyte and microglial infiltration, and neuronal death, were reported to be attenuated by TLR2 inhibition ([@b39-mmr-18-02-1513]), indicating a potential novel therapeutic strategy.

In conclusion, the current study identified a set of DEGs that were altered between cerebral I/R injury samples and sham control samples. The findings may provide novel insight into the potential mechanisms underlying the development of cerebral I/R injury. Our future studies will be aimed at unveiling the potential diagnostic and prognostic value of these hub genes, which may ultimately aid the translation of these targets into clinical practice.
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![Venn diagram presenting the DEGs between cerebral I/R and sham control samples at 2, 8 and 24 h post-reperfusion. A total of 15 DEGs were common among all three post-reperfusion time-points. DEGs, differentially expressed genes; I/R, ischemia/reperfusion.](MMR-18-02-1513-g00){#f1-mmr-18-02-1513}
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###### 

DEGs between cerebral I/R and sham control samples that were common among 2, 8 and 24 h post-reperfusion time-points.

                                                             Post-reperfusion time-point                                                  
  -------- ------------------------------------------------- ----------------------------- ---------- ------------ ---------- ----------- ----------
  ATF3     Activating transcription factor 3                 5.01×10-6                     2.026964   3.56×10-5    1.692171   7.49×10-3   1.591308
  CCL3     C-C motif chemokine ligand 3                      5.13×10-10                    3.259239   7.05×10-6    3.291652   4.81×10-4   2.300334
  CCL4     C-C motif chemokine ligand 4                      1.32×10-10                    4.429954   1.29×10-6    4.47245    5.83×10-5   3.679271
  CCL7     C-C motif chemokine ligand 7                      2.18×10-5                     1.220192   7.63×10-6    1.426973   4.00×10-3   1.707457
  CD14     CD14 antigen                                      1.38×10-7                     1.757282   5.92×10-7    2.578573   2.56×10-3   2.353608
  CXCL1    C-X-C motif chemokine ligand 1                    3.29×10-6                     1.806643   4.81×10-8    2.878735   1.43×10-3   2.596958
  EMP1     Epithelial membrane protein 1                     1.68×10-6                     1.688657   6.78×10-7    1.383669   1.89×10-3   2.161470
  GJB2     Gap junction protein β2                           3.16×10-8                     1.999569   1.15×10-7    1.717101   9.13×10-5   1.822626
  HBA-A1   Hemoglobin α, adult chain 1                       5.38×10-7                     2.436023   2.15×10-8    3.757753   4.48×10-4   3.807134
  HSPA1A   Heat shock protein 1A                             1.69×10-6                     3.054788   3.80×10-5    2.545466   1.59×10-2   1.299110
  LCN2     Lipocalin 2                                       4.06×10-9                     1.312245   4.47×10-15   3.250233   1.72×10-5   3.408973
  S100A8   S100 calcium-binding protein A8 (calgranulin A)   2.29×10-6                     1.240885   1.66×10-6    1.655962   1.90×10-3   3.780381
  SOCS3    Suppressor of cytokine signaling 3                3.54×10-8                     2.009771   1.74×10-8    2.004998   5.48×10-4   2.361302
  TIMP1    Tissue inhibitor of metalloproteinase 1           1.02×10-8                     2.376190   3.61×10-18   3.403190   1.52×10-5   3.874533
  ZFP36    Zinc finger protein 36                            2.01×10-5                     1.595428   6.26×10-7    1.404682   1.17×10-2   1.330419

###### 

Top 10 enriched GO biological process terms for DEGs between cerebral ischemia/reperfusion and sham control samples.

  A, Top 10 enriched GO biological process terms for DEGs at 2 h post-reperfusion                                                                                                                 
  -------------------------------------------------------------------------------------- ---------------------------------------------------------------------- ----------- ------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  GO:0030593                                                                             Neutrophil chemotaxis                                                  5           15.63   5.65×10-6     CXCL1, CCL3, S100A8, CCL4, CCL7
  GO:0032570                                                                             Response to progesterone                                               4           12.50   1.80×10-5     FOS, OXT, FOSB, GJB2
  GO:0006954                                                                             Inflammatory response                                                  7           21.88   2.24×10-5     CXCL1, CCL3, S100A8, CCL4, CCL7, CD14, IL1A
  GO:0045944                                                                             Positive regulation of transcription from RNA polymerase II promoter   10          31.25   2.99×10-5     FOS, CCL3, EGR2, ATF3, EGR4, FOSB, NPAS4, JUNB, IL1A, CYR61
  GO:0071356                                                                             Cellular response to tumor necrosis factor                             5           15.63   3.59×10-5     LCN2, ZFP36, CCL3, CCL4, CCL7
  GO:2000503                                                                             Positive regulation of natural killer cell chemotaxis                  3           9.38    4.25×10-5     CCL3, CCL4, CCL7
  GO:0006935                                                                             Chemotaxis                                                             5           15.63   4.73×10-5     CCL3, S100A8, CCL4, CCL7, CYR61
  GO:0051591                                                                             Response to cAMP                                                       4           12.50   8.99×10-5     FOS, OXT, FOSB, JUNB
  GO:0070098                                                                             Chemokine-mediated signaling pathway                                   4           12.50   1.13×10-4     CXCL1, CCL3, CCL4, CCL7
  GO:0050729                                                                             Positive regulation of inflammatory response                           4           12.50   1.69×10-4     CCL3, S100A8, CCL4, CCL7
                                                                                                                                                                                                  
  **B, Top 10 enriched GO biological process terms for DEGs at 8 h post-reperfusion**                                                                                                             
                                                                                                                                                                                                  
  **GO ID**                                                                              **GO term**                                                            **Count**   **%**   **P-value**   **Genes**
                                                                                                                                                                                                  
  GO:0030593                                                                             Neutrophil chemotaxis                                                  10          25.64   8.69×10-15    CXCL1, CCL12, CCL3, S100A8, LGALS3, CCL9, CCL4, CCL7, FCGR3, CCL17
  GO:0002548                                                                             Monocyte chemotaxis                                                    8           20.51   1.19×10-12    CCL12, CCL3, FLT1, LGALS3, CCL9, CCL4, CCL7, CCL17
  GO:0070098                                                                             Chemokine-mediated signaling pathway                                   7           17.95   1.09×10-9     CXCL1, CCL12, CCL3, CCL9, CCL4, CCL7, CCL17
  GO:0071356                                                                             Cellular response to tumor necrosis factor                             8           20.51   1.83×10-9     LCN2, ZFP36, CCL12, CCL3, CCL9, CCL4, CCL7, CCL17
  GO:0050729                                                                             Positive regulation of inflammatory response                           7           17.95   2.52×10-9     CCL12, CCL3, S100A8, CCL9, TLR2, CCL4, CCL7
  GO:0006935                                                                             Chemotaxis                                                             8           20.51   3.01×10-9     CCL12, CCL3, FLT1, S100A8, CCL9, CCL4, CCL7, CCL17
  GO:0071346                                                                             Cellular response to interferon-gamma                                  7           17.95   4.02×10-9     CCL12, CCL3, CCL9, CCL4, GBP2, CCL7, CCL17
  GO:0048247                                                                             Lymphocyte chemotaxis                                                  6           15.38   5.34×10-9     CCL12, CCL3, CCL9, CCL4, CCL7, CCL17
  GO:0071347                                                                             Cellular response to interleukin-1                                     7           17.95   1.09×10-8     LCN2, CCL12, CCL3, CCL9, CCL4, CCL7, CCL17
  GO:0006954                                                                             Inflammatory response                                                  10          25.64   1.76×10-8     CXCL1, CCL12, CCL3, S100A8, CCL9, TLR2, CCL4, CCL7, CD14, CCL17
                                                                                                                                                                                                  
  **C, Top 10 enriched GO biological process terms for DEGs at 24 h post-reperfusion**                                                                                                            
                                                                                                                                                                                                  
  **GO ID**                                                                              **GO term**                                                            **Count**   **%**   **P-value**   **Genes**
                                                                                                                                                                                                  
  GO:0006954                                                                             Inflammatory response                                                  21          22.83   1.99×10-16    CXCL1, CCL3, CCL2, S100A8, CCL21C, S100A9, CCL9, TLR2, CCL21A, PF4, FPR2, IDO1, CCL4, CCL7, CXCL10, SLC11A1, CYBA, CCL12, CHIL3, CD14, SPP1
  GO:0006955                                                                             Neutrophil chemotaxis                                                  13          14.13   5.60×10-16    CXCL1, CCL3, CCL2, S100A8, LGALS3, CCL21C, S100A9, CCL21A, CCL9, CCL4, CCL7, CCL12, SPP1
  GO:0006956                                                                             Chemokine-mediated signaling pathway                                   11          11.96   1.08×10-13    CXCL1, CCL12, CCL3, CCL2, CCL21C, CCL9, CCL21A, PF4, CCL4, CCL7, CXCL10
  GO:0006957                                                                             Monocyte chemotaxis                                                    9           9.78    1.54×10-11    CCL12, CCL3, CCL2, LGALS3, CCL21C, CCL9, CCL21A, CCL4, CCL7
  GO:0006958                                                                             Positive regulation of inflammatory response                           10          10.87   1.92×10-11    CCL12, CCL3, CCL2, S100A8, S100A9, CCL9, TGM2, TLR2, CCL4, CCL7
  GO:0006959                                                                             Cellular response to tumor necrosis factor                             11          11.96   1.39×10-10    LCN2, ZFP36, CCL12, CYBA, CCL3, CCL2, CCL21C, CCL9, CCL21A, CCL4, CCL7
  GO:0006960                                                                             Cellular response to interleukin-1                                     10          10.87   1.76×10-10    LCN2, CCL12, CCL3, CCL2, CCL21C, CCL9, SAA3, CCL21A, CCL4, CCL7
  GO:0006961                                                                             Lymphocyte chemotaxis                                                  8           8.70    1.96×10-10    CCL12, CCL3, CCL2, CCL21C, CCL9, CCL21A, CCL4, CCL7
  GO:0006962                                                                             Chemotaxis                                                             11          11.96   2.80×10-10    CCL12, CCL3, CCL2, S100A8, S100A9, CCL9, PF4, FPR2, CCL4, CCL7, CXCL10
  GO:0006963                                                                             Cellular response to interferon-gamma                                  9           9.78    1.33×10-9     CCL12, CCL3, CCL2, CCL21C, CCL9, CCL21A, CCL4, GBP2, CCL7

GO, Gene Ontology; DEGs, differentially expressed genes.

###### 

GO cellular component terms for DEGs between cerebral ischemia/reperfusion and sham control samples.

  A, Enriched GO cellular component terms for DEGs at 2 h post-reperfusion                                                                              
  ------------------------------------------------------------------------------- ----------------------------------- ----------- ------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO:0005576                                                                      Extracellular region                14          43.75   9.56×10-7     CXCL1, CCL3, AVP, S100A8, PMCH, OXT, CCL4, CCL7, TIMP1, LCN2, NPTX2, IL1A, CD14, CYR61
  GO:0005615                                                                      Extracellular space                 12          37.50   1.02×10-5     LCN2, CXCL1, AVP, CCL3, S100A8, PMCH, OXT, CCL4, CCL7, CD14, IL1A, TIMP1
                                                                                                                                                        
  **B, Enriched GO cellular component terms for DEGs at 8 h post-reperfusion**                                                                          
                                                                                                                                                        
  **GO ID**                                                                       **GO term**                         **Count**   **%**   **P-value**   **Genes**
                                                                                                                                                        
  GO:0005615                                                                      Extracellular space                 16          41.03   4.81×10-8     CXCL1, CCL3, FLT1, S100A8, LGALS3, PMCH, CCL9, CCL4, CCL7, TIMP1, CCL17, LCN2, CCL12, SERPINA3N, DMKN, CD14
  GO:0005576                                                                      Extracellular region                14          35.90   1.39×10-5     CXCL1, CCL3, S100A8, LGALS3, PMCH, CCL9, CCL4, CCL7, TIMP1, LCN2, CCL12, SERPINA3N, DMKN, CD14
  GO:0009897                                                                      External side of plasma membrane    5           12.82   3.17×10-3     LGALS3, OSMR, TLR2, CD14, FCGR3
  GO:0016020                                                                      Membrane                            20          51.28   4.79×10-2     GPR84, FLT1, S100A8, LGALS3, OSMR, FKBP5, MS4A6D, TLR2, SLC10A6, GJB2, FCGR3, HBA-A1, CH25H, PLIN4, HMOX1, ITGAD, SLC15A3, GBP2, EMP1, CD14
                                                                                                                                                        
  **C, Enriched GO cellular component terms for DEGs at 24 h post-reperfusion**                                                                         
                                                                                                                                                        
  **GO ID**                                                                       **GO term**                         **Count**   **%**   **P-value**   **Genes**
                                                                                                                                                        
  GO:0009897                                                                      External side of plasma membrane    8           8.70    6.31×10-4     FCGR2B, LGALS3, PDPN, CCL21C, FCGR4, TLR2, CD14, CXCL10
  GO:0048237                                                                      Rough endoplasmic reticulum lumen   3           3.26    4.29×10-4     LYZ2, LYZ1, CHIL3
  GO:0009986                                                                      Cell surface                        10          10.87   2.33×10-3     SLC11A1, THBD, FCGR2B, LGALS3, TNFRSF12A, IFITM3, FCGR4, TLR2, CD14, ANXA2
  GO:0005886                                                                      Plasma membrane                     34          36.96   8.00×10-3     GPR182, GPR84, S100A8, IFITM2, TNFRSF12A, IFITM3, VIM, S100A9, TLR2, CD52, FPR2, SLC11A1, P2RY6, DAB2, PLIN2, HMOX1, TGM2, STRA6, CLEC4D, ANGPT2, ACTB, PDPN, LILRB4A, GJB2, ANXA2, CYBA, THBD, FCGR2B, HSPB1, SCN4B, RGS9, EMP3, CD14, EMP1
  GO:0016020                                                                      Membrane                            44          47.83   1.14×10-2     GPR182, GPR84, GFAP, TSPO, S100A8, IFITM2, TNFRSF12A, IFITM3, S100A9, TLR2, CD52, FPR2, FXYD5, GLIPR2, SLC11A1, P2RY6, DAB2, PLIN2, HMOX1, CH25H, TGM1, TGM2, STRA6, CLEC4D, ACTB, LGALS3, PDPN, MS4A6D, LILRB4A, GJB2, ANXA2, HBA-A1, CYBA, RAB32, THBD, FCGR2B, SCN4B, RGS9, EMP3, SLC15A3, GBP2, CD14, EMP1, MVP

GO, Gene Ontology; DEGs, differentially expressed genes.

###### 

Enriched GO molecular function terms for DEGs between cerebral ischemia/reperfusion and sham control samples.

  A, Enriched GO molecular function terms for DEGs at 2 h post-reperfusion                                                                                                                                                          
  ------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ----------- ------- ------------- ----------------------------------------------------------------------------
  GO:0005125                                                                      Cytokine activity                                                                                               6           18.75   2.48×10-5     CXCL1, FOS, CCL3, CCL4, CD14, IL1A
  GO:0008009                                                                      Chemokine activity                                                                                              4           12.50   6.79×10-5     FOS, CCL3, CCL4, CD14
  GO:0000978                                                                      RNA polymerase II core promoter proximal region sequence-specific DNA binding                                   6           18.75   2.84×10-4     FOS, EGR2, ATF3, FOSB, NPAS4, JUNB
  GO:0001077                                                                      Transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding   5           15.63   9.82×10-4     FOS, EGR2, FOSB, NPAS4, JUNB
  GO:0003690                                                                      Double-stranded DNA binding                                                                                     3           9.38    2.13×10-2     FOS, FOSB, JUNB
  GO:0003677                                                                      DNA binding                                                                                                     8           25.00   2.85×10-2     ZFP36, FOS, EGR2, ATF3, EGR4, FOSB, NPAS4, JUNB
                                                                                                                                                                                                                                    
  **B, Enriched GO molecular function terms for DEGs at 8 h post-reperfusion**                                                                                                                                                      
                                                                                                                                                                                                                                    
  **GO ID**                                                                       **GO term**                                                                                                     **Count**   **%**   **P-value**   **Genes**
                                                                                                                                                                                                                                    
  GO:0008009                                                                      Chemokine activity                                                                                              7           17.95   3.98×10-10    CXCL1, CCL12, CCL3, CCL9, CCL4, CCL7, CCL17
  GO:0005125                                                                      Cytokine activity                                                                                               8           20.51   1.54×10-7     CXCL1, CCL12, CCL3, CCL9, CCL4, CCL7, CCL17, TIMP1
  GO:0048020                                                                      CCR chemokine receptor binding                                                                                  4           10.26   2.14×10-5     CCL3, CCL9, CCL4, CCL17
                                                                                                                                                                                                                                    
  **C, Enriched GO molecular function terms for DEGs at 24 h post-reperfusion**                                                                                                                                                     
                                                                                                                                                                                                                                    
  **GO ID**                                                                       **GO term**                                                                                                     **Count**   **%**   **P-value**   **Genes**
                                                                                                                                                                                                                                    
  GO:0008009                                                                      Chemokine activity                                                                                              11          11.96   1.69×10-14    CXCL1, CCL12, CCL3, CCL2, CCL21C, CCL9, CCL21A, PF4, CCL4, CCL7, CXCL10
  GO:0005125                                                                      Cytokine activity                                                                                               12          13.04   4.78×10-9     CXCL1, CCL12, CCL3, CCL2, CCL9, PF4, CCL4, CCL7, SPP1, TIMP1, CXCL10, IL11
  GO:0048020                                                                      CCR chemokine receptor binding                                                                                  5           5.44    8.52×10-6     CCL3, CCL21C, CCL9, CCL21A, CCL4
  GO:0031727                                                                      CCR2 chemokine receptor binding                                                                                 3           3.26    1.30×10-4     CCL12, CCL2, CCL7
  GO:0008201                                                                      Heparin binding                                                                                                 4           4.35    3.43×10-2     CCL2, PF4, CCL7, CXCL10
  GO:0020037                                                                      Heme binding                                                                                                    4           4.35    4.94×10-2     HBA-A1, CYBA, HMOX1, IDO1

GO, Gene Ontology; DEGs, differentially expressed genes.

###### 

Enriched KEGG pathways for DEGs between cerebral ischemia/reperfusion and sham control samples.

  A, Enriched KEGG pathways for DEGs at 2 h post-reperfusion                                                                                      
  ----------------------------------------------------------------- ------------------------------------------- ----------- ------- ------------- -----------------------------------------------------------------------------
  mmu05132                                                          Salmonella infection                        6           18.75   1.27×10-6     CXCL1, FOS, CCL3, CCL4, CD14, IL1A
  mmu04380                                                          Osteoclast differentiation                  5           15.63   2.68×10-4     FOS, SOCS3, FOSB, JUNB, IL1A
  mmu04620                                                          Toll-like receptor signaling pathway        4           12.50   2.11×10-3     FOS, CCL3, CCL4, CD14
  mmu04062                                                          Chemokine signaling pathway                 4           12.50   1.34×10-2     CXCL1, CCL3, CCL4, CCL7
  mmu04060                                                          Cytokine-cytokine receptor interaction      4           12.50   2.41×10-2     CCL3, CCL4, CCL7, IL1A
  mmu05166                                                          HTLV-I infection                            4           12.50   3.35×10-2     ZFP36, FOS, EGR2, ATF3
                                                                                                                                                  
  **B, Enriched KEGG pathways for DEGs at 8 h post-reperfusion**                                                                                  
                                                                                                                                                  
  **KEGG entry**                                                    **Pathway name**                            **Count**   **%**   **P-value**   **Genes**
                                                                                                                                                  
  mmu04062                                                          Chemokine signaling pathway                 7           17.95   2.28×10-5     CXCL1, CCL12, CCL3, CCL9, CCL4, CCL7, CCL17
  mmu04060                                                          Cytokine-cytokine receptor interaction      6           15.38   8.01×10-4     CCL12, CCL3, FLT1, OSMR, CCL4, CCL7
  mmu05132                                                          Salmonella infection                        4           10.26   1.72×10-3     CXCL1, CCL3, CCL4, CD14
  mmu04620                                                          Toll-like receptor signaling pathway        4           10.26   3.60×10-3     CCL3, TLR2, CCL4, CD14
  mmu04145                                                          Phagosome                                   4           10.26   1.61×10-2     TLR2, TUBB6, CD14, FCGR3
  mmu05142                                                          Chagas disease (American trypanosomiasis)   3           7.69    4.02×10-2     CCL12, CCL3, TLR2
                                                                                                                                                  
  **C, Enriched KEGG pathways for DEGs at 24 h post-reperfusion**                                                                                 
                                                                                                                                                  
  **KEGG entry**                                                    **Pathway name**                            **Count**   **%**   **P-value**   **Genes**
                                                                                                                                                  
  mmu04062                                                          Chemokine signaling pathway                 11          11.96   2.50×10-7     CXCL1, CCL12, CCL3, CCL2, CCL21C, CCL9, CCL21A, PF4, CCL4, CCL7, CXCL10
  mmu04060                                                          Cytokine-cytokine receptor interaction      11          11.96   1.95×10-6     CCL12, CCL3, CCL2, TNFRSF12A, CCL21C, CCL21A, PF4, CCL4, CCL7, CXCL10, IL11
  mmu05323                                                          Rheumatoid arthritis                        6           6.52    1.43×10-4     CCL12, CCL3, CCL2, TLR2, MMP3, IL11
  mmu04620                                                          Toll-like receptor signaling pathway        6           6.52    3.80×10-4     CCL3, TLR2, CCL4, CD14, SPP1, CXCL10
  mmu04668                                                          TNF signaling pathway                       6           6.52    5.41×10-4     CXCL1, CCL12, CCL2, SOCS3, MMP3, CXCL10
  mmu04145                                                          Phagosome                                   7           7.61    6.73×10-4     ACTB, CYBA, FCGR2B, FCGR4, TLR2, TUBB6, CD14
  mmu05144                                                          Malaria                                     4           4.35    3.20×10-3     HBA-A1, CCL12, CCL2, TLR2
  mmu05164                                                          Influenza A                                 6           6.52    3.99×10-3     ACTB, CCL12, CCL2, SOCS3, HSPA1A, CXCL10
  mmu05142                                                          Chagas disease (American trypanosomiasis)   4           4.35    2.58×10-2     CCL12, CCL3, CCL2, TLR2

KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes.

###### 

Hub genes identified in PPI networks.

  A, Hub genes in the PPI network at 2 h post-reperfusion        
  -------------------------------------------------------------- ------------
  FOS                                                            16
  CXCL1                                                          11
  ATF3                                                           11
                                                                 
  **B, Hub genes in the PPI network at 8 h post-reperfusion**    
                                                                 
  **Gene**                                                       **Degree**
                                                                 
  TLR2                                                           14
  CXCL1                                                          13
  CD14                                                           12
  CCL4                                                           12
  CCL3                                                           12
  CCL7                                                           12
  TIMP1                                                          10
                                                                 
  **C, Hub genes in the PPI network at 24 h post-reperfusion**   
                                                                 
  **Gene**                                                       **Degree**
                                                                 
  CCL2                                                           37
  TLR2                                                           28
  CCL3                                                           19
  CD14                                                           19
  CXCL10                                                         19
  CXCL1                                                          18
  CCL7                                                           17
  CCL4                                                           17
  SLC11A1                                                        16
  TIMP1                                                          16
  MS4A6D                                                         14
  LCN2                                                           14
  LILRB4                                                         14
  FPR2                                                           14
  SOCS3                                                          13
  SLC15A3                                                        12
  VIM                                                            12
  FCGR2B                                                         12
  CCL9                                                           12
  CCL12                                                          11
  PF4                                                            11
  LGALS3                                                         10
  ACTB                                                           10

PPI, protein-protein interaction.
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